Association between epithelial-mesenchymal transition and cancer stemness and their effect on the prognosis of lung adenocarcinoma

English version České info

Abstract:
The epithelial-mesenchymal transition (EMT) and cancer stemness (CS) are reported to be pivotal phenomena involved in metastasis, recurrence, and drug-resistance in lung cancer; however, their effects on tumor malignancy in clinical settings are not completely understood. The mutual association between these factors also remains elusive and are worthy of investigation. The purpose of this study was to elucidate the association between EMT and CS, and their effect on the prognosis of patients with lung adenocarcinoma. A total of 239 lung adenocarcinoma specimens were collected from patients who had undergone surgery at Kyoto University Hospital from January 2001 to December 2007. Both EMT (E-cadherin,vimentin) and CS (CD133, CD44, aldehyde dehydrogenase) markers were analyzed through immunostaining of tumor specimens. The association between EMT and CS as well as the patients' clinical information was integrated and statistically analyzed. The molecular expression of E-cadherin, vimentin, and CD133 were significantly correlated with prognosis (P = 0.003, P = 0.005, andP < 0.001). A negative correlation was found between E-cadherin and vimentin expression (P < 0.001), whereas, a positive correlation was found between vimentin and CD133 expression (P = 0.020). CD133 was a stronger prognostic factor than an EMT marker. Elevated CD133 expression is the signature marker of EMT and CS association in lung adenocarcinoma. EMT and CS are associated in lung adenocarcinoma. Importantly, CD133 is suggested to be the key factor that links EMT and CS, thereby exacerbating tumor progression.

Keywords:
Cancer stemness; CD133; epithelial-mesenchymal transition; lung adenocarcinoma; vimentin

Autoři: Terumasa Sowa ¹; Toshi Menju ¹; Makoto Sonobe ¹; Takao Nakanishi ¹; Kei Shikuma ¹; Naoto Imamura ¹; Hideki Motoyama ¹; Kyoko Hijiya ¹; Akihiro Aoyama ¹; Fengshi Chen ¹; Toshihiko Sato ¹; Masashi; Kobayashi ²; Akihiko Yoshizawa ³; Hironori Haga ³; Takashi Sozu ⁴; Hiroshi Date ¹
Působiště autorů: Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan ¹; Department of Thoracic Surgery, Tokyo Medical and Dental University, Tokyo, Japan ²; Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan ³; Department of Management Science, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan ⁴
Vyšlo v časopise: Cancer Medicine 2015; Early View(Early View)
Kategorie: Original Research
prolekare.web.journal.doi_sk: https://doi.org/10.1002/cam4.556

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Souhrn

Keywords:
Cancer stemness; CD133; epithelial-mesenchymal transition; lung adenocarcinoma; vimentin

Zdroje

1. Torre, L. A., F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal. 2015. Global cancer statistics, 2012. CA Cancer J. Clin. 65:95–96.

2. Devesa, S. S., F. Bray, A. P. Vizcaino, and D. M. Parkin. 2005. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int. J. Cancer 117:294–299.

3. Greenburg, G., and E. D. Hay. 1982. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J. Cell Biol. 95:333–339.

4. Kalluri, R., and R. A. Weinberg. 2009. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119:1420–1428.

5. Ivaska, J. 2011. Vimentin: central hub in EMT induction? Small GTPases 2:51–53.

6. Thiery, J. P. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2:442–454.

7. Franke, W. W., E. Schmid, M. Osborn, and K. Weber. 1978. Different intermediate-sized filaments distinguished by immunofluorescence microscopy. Proc. Natl. Acad. Sci. USA 75:5034–5038.

8. Derycke, L. D., and M. E. Bracke. 2004. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int. J. Dev. Biol. 48:463–476.

9. Nieto, M. A. 2002. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 3:155–166.

10. Yang, J., S. A. Mani, J. L. Donaher, S. Ramaswamy, R. A. Itzykson, C. Come, et al. 2004. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939.

11. Vuoriluoto, K., H. Haugen, S. Kiviluoto, J. P. Mpindi, J. Nevo, C. Gjerdrum, et al. 2011. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 30:1436–1448.

12. Satelli, A., and S. Li. 2011. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 68:3033–3046.

13. Bonnet, D., and J. E. Dick. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3:730–737.

14. Al-Hajj, M., M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100:3983–3988.

15. Ricci-Vitiani, L., D. G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle, et al. 2007. Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115.

16. Li, C., D. G. Heidt, P. Dalerba, C. F. Burant, L. Zhang, V. Adsay, et al. 2007. Identification of pancreatic cancer stem cells. Cancer Res. 67:1030–1037.

17. Singh, S. K., I. D. Clarke, M. Terasaki, V. E. Bonn, C. Hawkins, J. Squire, et al. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828.

18. Lobo, N. A., Y. Shimono, D. Qian, and M. F. Clarke. 2007. The biology of cancer stem cells. Ann. Rev. Cell Dev. Biol. 23:675–699.

19. Rapp, U. R., F. Ceteci, and R. Schreck. 2008. Oncogene-induced plasticity and cancer stem cells. Cell Cycle 7:45–51.

20. Monteiro, J., and R. Fodde. 2010. Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur. J. Cancer 46:1198–1203.

21. Shibahara, I., Y. Sonoda, R. Saito, M. Kanamori, Y. Yamashita, T. Kumabe, et al. 2013. The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro. Oncol. 15:1151–1159.

22. Artells, R., I. Moreno, T. Diaz, F. Martinez, B. Gel, A. Navarro, et al. 2010. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur. J. Cancer 46:642–649.

23. Ohara, Y., T. Oda, M. Sugano, S. Hashimoto, T. Enomoto, K. Yamada, et al. 2013. Histological and prognostic importance of CD44(+)/CD24(+)/EpCAM(+) expression in clinical pancreatic cancer. Cancer Sci. 104:1127–1134.

24. Silva, I. A., S. Bai, K. McLean, K. Yang, K. Griffith, D. Thomas, et al. 2011. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71:3991–4001.

25. Alamgeer, M., V. Ganju, A. Szczepny, P. A. Russell, Z. Prodanovic, B. Kumar, et al. 2013. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax 68:1095–1104.

26. Luo, Z., R. R. Wu, L. Lv, P. Li, L. Y. Zhang, Q. L. Hao, et al. 2014. Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review. Int. J. Clin. Exp. Pathol. 7:3632–3646.

27. Wu, H., X. W. Qi, G. N. Yan, Q. B. Zhang, C. Xu, and X. W. Bian. 2014. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis. PLoS ONE 9:e100168.

28. Mani, S. A., W. Guo, M. J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715.

29. Sobin, L. H. G. M., and C. Wittekind. 2009. TNM classification of malignant tumours. 7th ed. John Wiley & Sons, New York.

30. Travis, W. D., E. Brambilla, H. K. Muller-Hermelink, and C. C. Harris. 2004. Pathology & Genetics Tumours of the Lung, Pleura, Thymus and Heart. France, Lyon. IARC Press.

31. Travis, W. D., E. Brambilla, M. Noguchi, A. G. Nicholson, K. R. Geisinger, Y. Yatabe, et al. 2011. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 6:244–285.

32. Yoshizawa, A., S. Sumiyoshi, M. Sonobe, M. Kobayashi, T. Uehara, M. Fujimoto, et al. 2014. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer 85:373–378.

33. Kononen, J., L. Bubendorf, A. Kallioniemi, M. Barlund, P. Schraml, S. Leighton, et al. 1998. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4:844–847.

34. Toda, Y., K. Kono, H. Abiru, K. Kokuryo, M. Endo, H. Yaegashi, et al. 1999. Application of tyramide signal amplification system to immunohistochemistry: a potent method to localize antigens that are not detectable by ordinary method. Pathol. Int. 49:479–483.

35. Pirozzi, G., V. Tirino, R. Camerlingo, R. La Franco, A. Rocca, E. Liguori, et al. 2011. Epithelial to mesenchymal transition by TGFbeta-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS ONE 6:e21548.

36. Yin, A. H., S. Miraglia, E. D. Zanjani, G. Almeida-Porada, M. Ogawa, A. G. Leary, et al. 1997. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012.

37. Tirino, V., R. Camerlingo, K. Bifulco, E. Irollo, R. Montella, F. Paino, et al. 2013. TGF-beta1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Cell Death Dis. 4:e620.

38. Cufi, S., R. Bonavia, A. Vazquez-Martin, C. Oliveras-Ferraros, B. Corominas-Faja, E. Cuyas, et al. 2013. Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Sci. Rep. 3:2459.

39. Singh, R. P., K. Raina, G. Sharma, and R. Agarwal. 2008. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin. Cancer Res. 14:7773–7780.

40. Dong, T. T., H. M. Zhou, L. L. Wang, B. Feng, B. Lv, and M. H. Zheng. 2011. Salinomycin selectively targets ‘CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann. Surg. Oncol. 18:1797–1804.

41. Sahlgren, C., M. V. Gustafsson, S. Jin, L. Poellinger, and U. Lendahl. 2008. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Natl. Acad. Sci. USA 105:6392–6397.

42. Liang, D., Y. Ma, J. Liu, C. G. Trope, R. Holm, J. M. Nesland, et al. 2012. The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 12:201.

43. Nakagiri, T., N. Sawabata, E. Morii, M. Inoue, Y. Shintani, S. Funaki, et al. 2014. Evaluation of the new IASLC/ATS/ERS proposed classification of adenocarcinoma based on lepidic pattern in patients with pathological stage IA pulmonary adenocarcinoma. Gen. Thorac. Cardiovasc. Surg. 62:671–677.

44. Sterlacci, W., S. Savic, M. Fiegl, E. Obermann, and A. Tzankov. 2014. Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization. J. Thorac. Oncol. 9:41–49.

45. Goya, T., H. Asamura, H. Yoshimura, H. Kato, K. Shimokata, R. Tsuchiya, et al. 2005. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50:227–234.